Peter Hillmen, MD, PhD.PNH SCIENTIFIC ADVISORY BOARD
Professor of Experimental Hematology, Leeds Institute of Cancer & Pathology, UK
Peter Hillmen is Professor of Experimental Hematology and Honorary Consultant Hematologist at Leeds Teaching Hospitals NHS Trust. Professor Hillmen qualified in Medicine at Leeds Medical School in 1985 and completed his general medical training in Leeds in 1988. He was a Haematology Registrar in Hammersmith Hospital, London between 1989 and 1990 before completing three years as a Wellcome Training Fellow based at the Royal Postgraduate Medical School (1991 to 1993) completing a PhD working on PNH under the supervision of Professor Lucio Luzzatto. He then moved back to Leeds as a Senior Registrar in Hematology, Yorkshire (1994 to 1996). He was appointed as a Consultant Hematologist at Mid-Yorkshire Trust and Leeds General Infirmary in 1996 before moving to Leeds Teaching Hospitals NHS Trust in 2004. He was appointed as Professor of Experimental Hematology, University of Leeds in 2013.
Professor Hillmen has research interests in both paroxysmal nocturnal hemoglobinuria (PNH) and chronic lymphocytic leukemia (CLL). Since 1990 he has continued to research into PNH that eventually led to the development of anti-complement therapy for PNH, Eculizumab. He was the lead on the trials of eculizumab and now leads the National PNH Service based in Leeds and Kings. The National PNH service looks after over 300 patients with PNH and this provides a unique resource for continued research into the pathophysiology and therapy of PNH. Since 1995 Professor Hillmen has had an interest in understanding the pathophysiology of and in developing novel therapies for CLL. His group has pioneered the use of minimal residual disease assessment in CLL and he Chairs the NCRI CLL sub-group in the UK responsible for the development of UK CLL Clinical Trials. He initially studied chemo-immunotherapeutic approaches for CLL but recently the development of targeted small molecules, particularly of the B-cell receptor pathway and of apoptosis, has led to a dramatic change in the treatment of CLL. His research is now focusing on the mechanism of action of these targeted therapies in order to maximize their potential.